Abbreviations: ADC= adenocarcinoma; CI= confidence interval; DEIA= DNA enzyme immune assay; FIGO= Federation of Gynecology and Obstetrics; HPV= human papillomavirus; ICC= invasive cervical cancer; LiPA 25 = line probe assay using 25 typespecific hybridization probes; SCC= squamous cell carcinoma; PCR= polymerase chain reaction;
Introduction
In African women, invasive cervical cancer (ICC) is the second most common cancer and leading cause of cancer death. 1, 2 The high incidence of ICC in developing countries may be explained by low awareness and inability to successfully implement nationwide screening programs. 3 The number of deaths from ICC is nearly 10 times greater in these countries than in developed regions, and this is mainly due to lack of access to anti-cancer therapy combined with late presentation. 3, 4 In sub-Saharan Africa, over 70,000 new cases occur annually, and ICC is responsible for 25% of all female cancers and has an estimated overall agestandardized incidence rate of 31.0 per 100,000 women. 1, 2, [4] [5] [6] This is far higher than the overall age-standardized incidence rate of 11.9 per 100,000 women observed in Europe. 5, 6 Persistent infection with an oncogenic human papillomavirus (HPV) type has been identified as the necessary cause for the development of ICC. 3, [7] [8] [9] More than 40 different HPV types are known to infect the genital tract and 15 of these have been classified as oncogenic to humans. 5, [10] [11] [12] [13] [14] Women are exposed to genital HPV infections when they become sexually active and remain at risk throughout their lives. 15, 16 The necessary role of HPV infection in the development of ICC provides an opportunity to reduce disease burden through early diagnosis using HPV testing and prevention programs including prophylactic HPV vaccination.
The primary objectives of this study were to assess the prevalence of HPV in adult women with ICC in sub-Saharan Africa (Ghana, Nigeria, and South Africa) and the distribution of the most commonly detected HPV types. This is the first study using a standardized protocol for sampling and HPV typing to look specifically at HPV type distribution in sub-Saharan African women with ICC, which is important to evaluate the potential impact of prophylactic vaccines in this region.
Material and Methods

Study design and population
This cross-sectional, multicenter, epidemiological study was conducted in women aged ³21 years from Ghana, Nigeria, and South Africa, who had cervical lesions clinically suggestive of ICC. Women who had previously received chemo-or radiotherapy for cervical cancer were excluded. Cervical biopsy specimens were obtained by a gynecologist as part of routine investigative procedures at the participating hospital. Women who underwent a cervical biopsy received a questionnaire to evaluate their socio-demographic characteristics, 
Laboratory procedures
Cervical biopsy specimens obtained were immediately fixed in 10% buffered formalin, processed for paraffin wax embedding, and checked for quality. Biopsy samples that could not be immediately sent for paraffin embedding were stored in 10% buffered formalin in a firmly-closed screw-top container at room temperature (15-25°C) in the dark for a maximum of 7 days. Histopathological diagnosis of ICC was determined by light microscopy examination of hematoxylin and eosin stained sections of cervical specimens. The remainder of tissue blocks from women diagnosed with ICC was stored at a temperature of 4-35°C before being shipped to the central laboratory.
At the central laboratory, samples with a confirmed histopathological diagnosis of ICC underwent HPV DNA typing using SPF 10 PCR-DEIA-LiPA 25 version 1 system (Labo Biomedical Products, The Netherlands; based on SPF 10 licensed Innogenetics technology).
18,19
Total DNA was isolated and extracted using a proteinase K lysis procedure. DNA was amplified by SPF 10 and generic amplification products were detected by DNA probe hybridization and DNA enzyme immune assay (DEIA). HPV-positive specimens were typed by reverse hybridization line probe assay using 25 type-specific hybridization probes (LiPA 25 ), which detected 14 high-risk (HPV16, HPV18, HPV31, HPV33, HPV35, HPV39,   HPV45, HPV51, HPV52, HPV56, HPV58, HPV59, HPV66, HPV68/73) and 11 low-risk   (HPV6, HPV11, HPV34, HPV40, HPV42, HPV43, HPV44, HPV53, HPV54, HPV70, HPV74) types, as previously described. 20 Samples that were DEIA-positive and LiPA 25 -negative were classified as HPV untypeable. Positive and negative controls were used to monitor DNA isolation, polymerase chain reaction (PCR) amplification, HPV detection, and typing procedures. The DNA of HPV-negative samples was diluted tenfold and testing was repeated to rule out inhibitors in the sample being responsible for negative results rather than true absence of HPV.
Statistical analysis
Three cohorts were used for analysis: the total enrolled cohort included all women enrolled in the study; the histologically confirmed cohort included all enrolled women with confirmed diagnosis of ICC; and the HPV-positive cohort included all women from the histologically confirmed cohort with a positive HPV DNA status.
In each country, 238 enrolled women with ICC were needed to reach the target of 193 proportions of women infected with HPV16 and HPV18 were evaluated between countries.
All statistical analyses were performed using SAS ® software (version 9.2). Table 2 .
Results
Demographics
HPV type distribution
In the histologically confirmed cohort, the HPV-positivity rate was 90. In the 447 women with single HPV infection, HPV16 accounted for 51.2% of cases, followed by HPV18 (17.2%), HPV35 (8.7%), HPV45 (7.4%), HPV33 (4.0%), and HPV52 (2.2%) ( Table 3) . Although HPV16 was the dominant HPV type in all countries, exploratory analyses suggested that the relative proportion of women with single HPV16 infection was higher in Ghana than in South Africa. The relative proportion of women with single HPV18 infection tended to be greater in Ghana than in Nigeria.
The most commonly detected HPV types in the 394 women with SCC with single HPV infection were HPV16 (53.8%), HPV18 (15.0%), HPV35 (9.4%), and HPV45 (7.1%) ( Table   4 ). The most commonly detected HPV types in the limited sample of women with ADC (N=27) with single HPV infection were HPV18 (29.6%), HPV16 (22.2%), and HPV45
(18.5%). Table 5 ).
The most frequently detected HPV types in the 57 women with multiple HPV infections, in whom types that actually caused the lesion were not identified, were HPV16 (56.1%), HPV18
(38.6%), HPV45 (33.3%), HPV52 (22.8%), and HPV35 (19.3%) ( Table 6 ). In these women, HPV52 tended to be identified more frequently in Ghana (31.0%) and Nigeria (33.3%) than in South Africa (9.1%).
Discussion
This cross-sectional study assessed the HPV type distribution in women diagnosed with ICC in sub-Saharan. This is the first study conducted in Africa using standardized and validated methods for HPV DNA detection and testing, as well as centralized pathology review for confirmation of the histological diagnosis. In this study, the prevalence of HPV infection was higher in HIV-positive women, who are more likely to have multiple HPV infections. Although the total number of HIV-positive women was relatively low and the overall proportion of women with unknown HIV status was high in the present study, this observation is in line with previous findings on the prevalence of HPV infection in HIV-positive women with ICC in sub-Saharan Africa. [25] [26] Moreover, in South Africa, where the HIV status of almost 90% of women was known in the present study, the prevalence of single and multiple HPV infections was also higher among HIV-positive women than among HIV-negative women. This observation may be explained by the common sexual mode of transmission of HPV and HIV or by the potential reactivation of latent HPV infections as a result of immune suppression. Although previous studies reported that HPV52 was more frequently identified in HIV-positive than in HIV-negative women, the number of HIV-positive women was too low in the present study to confirm this finding. [27] [28] [29] Estimating shown that both vaccines had clinically acceptable safety profiles, were highly immunogenic and efficacious, and offered protection against infection with the vaccine types and their associated cytological and histological outcomes in adolescent girls and young women.
32-49
Cervarix ® has demonstrated >90% vaccine efficacy against cervical intraepithelial neoplasia grade 3 or worse, irrespective of the HPV type, and also cross-protective efficacy against four oncogenic non-vaccine types (HPV31, HPV33, HPV45, and HPV51). 46, 47, 49 Gardasil ™ has also demonstrated cross-protective efficacy against HPV31. 50 Here, HPV16 and HPV18
accounted for 68.4% of ICC cases in women with single HPV infection, ranging from 65.5%
of cases in South Africa to 74.4% of cases in Ghana.
Strengths of this study included the standardized protocol used in the three countries, the central histopathological assessment with blinded expert review, the well-validated, highlysensitive method used for HPV DNA detection, and the typing process enabling detection of a broad spectrum of HPV types. This study addresses an important data gap since there is virtually no good epidemiological evidence of HPV type distribution in women with ICC in sub-Saharan Africa, but was limited by the fact that it only included one South-and two West-African countries, with no East-African representation. This study was not powered to observe differences between regions of sub-Saharan Africa and the results of the exploratory comparison between countries in terms of relative contributions of HPV16 and HPV18 in ICC should be interpreted with caution. The high rate of women with unknown HIV status, the fact that 54/66 HIV-positive women were from South Africa, and the lack of confirmation of HIV status in the other countries might have introduced potential bias. Limitations included also the low number of ADC cases, the relatively high proportion of women in whom the HPV type could not be determined, and the absence of identification of the HPV type actually causing the lesion in women with multiple infections.
In conclusion, HPV positivity rates were high as expected in women with ICC in subSaharan Africa, and HPV16, HPV18, HPV35, HPV45, HPV33, and HPV52 were the most commonly detected types in women with single HPV infection. Implementation of prophylactic HPV vaccination in adolescent girls and women may reduce the disease burden of ICC in this region.
Cervarix is a registered trademark of the GlaxoSmithKline group of companies
Gardasil is a trademark of Merck & Co., Inc.
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